These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Qian J, Hirasawa K, Bostwick DG, Bergstralh EJ, Slezak JM, Anderl KL, Borell TJ, Lieber MM, Jenkins RB. Mod Pathol; 2002 Jan 15; 15(1):35-44. PubMed ID: 11796839 [Abstract] [Full Text] [Related]
5. Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients. Sato H, Minei S, Hachiya T, Yoshida T, Takimoto Y. Int J Urol; 2006 Jun 15; 13(6):761-6. PubMed ID: 16834657 [Abstract] [Full Text] [Related]
6. Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone. Alers JC, Krijtenburg PJ, Rosenberg C, Hop WC, Verkerk AM, Schröder FH, van der Kwast TH, Bosman FT, van Dekken H. Lab Invest; 1997 Nov 15; 77(5):437-48. PubMed ID: 9389787 [Abstract] [Full Text] [Related]
7. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Bethel CR, Faith D, Li X, Guan B, Hicks JL, Lan F, Jenkins RB, Bieberich CJ, De Marzo AM. Cancer Res; 2006 Nov 15; 66(22):10683-90. PubMed ID: 17108105 [Abstract] [Full Text] [Related]
8. Biologic markers in prostatic intraepithelial neoplasia: immunohistochemical and cytogenetic analyses. Tsuji M, Kanda K, Murakami Y, Kurokawa Y, Kanayama H, Sano T, Kagawa S. J Med Invest; 1999 Feb 15; 46(1-2):35-41. PubMed ID: 10408155 [Abstract] [Full Text] [Related]
9. Detection of c-myc amplification in uveal melanoma by fluorescent in situ hybridization. Parrella P, Caballero OL, Sidransky D, Merbs SL. Invest Ophthalmol Vis Sci; 2001 Jul 15; 42(8):1679-84. PubMed ID: 11431428 [Abstract] [Full Text] [Related]
11. Chromosome 8 numerical aberration and C-MYC copy number gain in bladder cancer are linked to stage and grade. Mahdy E, Pan Y, Wang N, Malmström PU, Ekman P, Bergerheim U. Anticancer Res; 2001 Jul 15; 21(5):3167-73. PubMed ID: 11848469 [Abstract] [Full Text] [Related]
12. High-grade prostate intraepithelial neoplasia shares cytogenetic alterations with invasive prostate cancer. Alcaraz A, Barranco MA, Corral JM, Ribal MJ, Carrió A, Mallofré C, Llopis J, Cetina A, Alvarez-Vijande R. Prostate; 2001 Apr 15; 47(1):29-35. PubMed ID: 11304727 [Abstract] [Full Text] [Related]
16. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. Kraehn GM, Utikal J, Udart M, Greulich KM, Bezold G, Kaskel P, Leiter U, Peter RU. Br J Cancer; 2001 Jan 05; 84(1):72-9. PubMed ID: 11139316 [Abstract] [Full Text] [Related]
18. c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance. Schleger C, Verbeke C, Hildenbrand R, Zentgraf H, Bleyl U. Mod Pathol; 2002 Apr 05; 15(4):462-9. PubMed ID: 11950922 [Abstract] [Full Text] [Related]
19. Aneusomies of chromosomes 8 and Y detected by fluorescence in situ hybridization are prognostic markers for pathological stage C (pt3N0M0) prostate carcinoma. Takahashi S, Alcaraz A, Brown JA, Borell TJ, Herath JF, Bergstralh EJ, Lieber MM, Jenkins RB. Clin Cancer Res; 1996 Jan 05; 2(1):137-45. PubMed ID: 9816100 [Abstract] [Full Text] [Related]
20. Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray. Skacel M, Ormsby AH, Pettay JD, Tsiftsakis EK, Liou LS, Klein EA, Levin HS, Zippe CD, Tubbs RR. Hum Pathol; 2001 Dec 05; 32(12):1392-7. PubMed ID: 11774175 [Abstract] [Full Text] [Related] Page: [Next] [New Search]